Why the study?
Does P2Y12 inhibitor monotherapy compared to dual-antiplatelet therapy improve outcomes in patients after acute coronary syndromes or coronary stent implantation?
Does P2Y12 inhibitor monotherapy compared to dual-antiplatelet therapy improve outcomes in patients after acute coronary syndromes or coronary stent implantation?
This review questions the long-standing paradigm of aspirin use for secondary prevention after ACS or stenting, suggesting P2Y12 monotherapy may be a justified 'less-is-more' strategy.
Questions aspirin-centric secondary prevention post-ACS; hypothesis-generating for P2Y12 monotherapy and requires RCTs before practice change.
inhibitors alone versus dual-antiplatelet therapy after acute coronary syndromes or coronary stent implantation. As the availability of more effective antiplatelet agents increases, it is time to revisit the existing and long-standing paradigm supporting aspirin use for secondary prevention of atherothrombotic events. Ongoing trials will provide new evidence whether the less-is-more strategy is justified.
No takes yet. Share an insight, caveat, or question.
Gargiulo et al. (2016) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: